We have previously demonstrated the ability of 5′ and 6′-isonucleosides to inhibit the activity of acetylcholinesterase, a major target for Alzheimer’s disease therapy. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.